Results 101 to 110 of about 8,202 (206)

Comparing the effects of biguanides and dipeptidyl peptidase-4 inhibitors on cardio-cerebrovascular outcomes, nephropathy, retinopathy, neuropathy, and treatment costs in diabetic patients.

PLoS ONE
BackgroundWestern guidelines often recommend biguanides as the first-line treatment for diabetes. However, dipeptidyl peptidase-4 (DPP-4) inhibitors, alongside biguanides, are increasingly used as the first-line therapy for type 2 diabetes (T2DM) in ...
Eiji Nakatani, Hiromitsu Ohno, Tatsunori Satoh, Daito Funaki, Chikara Ueki, Taku Matsunaga, Takayoshi Nagahama, Toru Tonoike, Hiromichi Yui, Akinori Miyakoshi, Yoshihiro Tanaka, Ataru Igarashi, Hiraku Kumamaru, Nagato Kuriyama, Akira Sugawara   +14 more
doaj   +1 more source

Comparative Analysis of Chlorhexidine Derivatives and Alternative Agents on Streptococcus mutans Viability, Biofilm Formation, and Gene Expression

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Chlorhexidine gluconate and alexidine potently kill S. mutans, disrupt biofilms, and downregulate virulence genes, yet show moderate cytotoxicity. In contrast, sub‐MIC amoxicillin paradoxically promotes biofilm formation, highlighting the need for targeted antibiofilm therapies. ABSTRACT This study evaluates the antimicrobial and antibiofilm effects of
Hamideh Kamalloo, Mohammadreza Moeininejad, Maryam kiani golshoui, Fatemeh Samadyar, Ali Shivaee, Behrooz Sadeghi Kalani   +5 more
wiley   +1 more source

Type 2 Diabetes Mellitus: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 8, August 2026.
This graphical summary illustrates the multiorgan therapeutic landscape for Type 2 diabetes mellitus (T2D), integrating molecular pathogenesis with modern treatment strategies. It depicts how current interventions, including SGLT2 inhibitors, GLP‐1 receptor agonists, and insulin secretagogues, target key organs—kidney, pancreas, gastrointestinal tract,
Shinuan Fei, Xiyue Xiong, Lu Zhang, Jian Zhang, Lawrence W. C. Chan, Hong Jiang, Qingqing Xiong, Changtao Hu, Jie Chen, Sijun Yang   +9 more
wiley   +1 more source

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8724-8728, September 2026.
Juan Manuel Arteaga‐Diaz, Jose Luis Torres‐Grajales, Leobardo Sauque‐Reyna, Carlos Salamanca‐Carrillo, Luis Anguiano‐Medrano   +4 more
wiley   +1 more source

Mapping Obesity Care Pathways and Healthcare Resource Use From 2015 to 2019 in England

Obesity Science &Practice, Volume 12, Issue 4, August 2026.
ABSTRACT Objective This observational study characterized obesity care pathways and healthcare resource use in England between 2015 and 2019. Methods Data were obtained from Discover and the Salford Integrated Record (SIR), two databases of linked primary and secondary electronic health records in England. Adults with a body mass index (BMI) ≥ 30 kg/m2
Alexander Dimitri Miras, Silvia Capucci, Sylwia Migas, Bozydar Wrona, Liwei Zhao, Johann Castañeda‐Sanabria, Lise M. Hagelund, Vasileios Antavalis, Camilla S. Morgen   +8 more
wiley   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source

Characterization of Usage Patterns of Drugs Suspected to Cause Adverse Drug Reactions in Older Hospitalized Patients

Geriatrics &Gerontology International, Volume 26, Issue 8, August 2026.
ABSTRACT Aim This study aimed to characterize the usage patterns of drugs suspected to cause adverse drug reactions (ADRs) in older hospitalized patients. Methods Medical records of older adults admitted to the Department of Geriatrics and Hypertension at Osaka University Hospital from September 2014 to August 2021 were reviewed.
Mizuki Katsuhisa, Shota Hamada, Chie Hamaie, Yuko Takeshita, Kasumi Ikuta, Yuichiro Saizen, Eriko Koujiya, Yoichi Takami, Koichi Yamamoto, Yasushi Takeya   +9 more
wiley   +1 more source

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1367-1378, August 2026.
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi, Jimin Jeon, Minyoul Baik, Joonsang Yoo, Jinkwon Kim   +4 more
wiley   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, Volume 27, Issue 8, August 2026.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Pharmacological treatment patterns, factors associated with glycemic control, and renal function parameters in a real-world cohort of Hispanic adults with type 2 diabetes. [PDF]

Biomed Rep
Diaz-Martinez J, Duran C, Hospital M, Hernández-Fuentes GA, Rojas-Larios F, Kallus L, Mancilla J, Jean-Pierre A, Barthe A, Madruga-Reyes Y, Parra-Vidal L, Wagner E, Bursac Z, Montesinos-López OA, Delgado-Enciso I.   +14 more
europepmc   +1 more source